公开(公告)号：US20240240176A1

公开(公告)日：2024-07-18

申请号：US18288887

申请日：2022-04-28

Applicant: KYOTO UNIVERSITY ,  OSAKA UNIVERSITY ,  MITSUBISHI TANABE PHARMA CORPORATION ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Jun KOTERA ,  Koh ONO ,  Takahiro HORIE ,  Naoya SOWA ,  Yuya IDE ,  Satoshi OBIKA ,  Yuya KASAHARA

IPC: C12N15/113 ,  A61P21/00

CPC classification number: C12N15/113 ,  A61P21/00 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/323 ,  C12N2310/531

Abstract: A prophylactic or therapeutic agent for a myopathy, including a miR-33b inhibitor, preferably an antisense oligonucleotide against miR-33b, as an effective component.

公开(公告)号：US20230159924A1

公开(公告)日：2023-05-25

申请号：US17905442

申请日：2021-03-02

Applicant: MITSUBISHI TANABE PHARMA CORPORATION ,  KYOTO UNIVERSITY ,  OSAKA UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Jun KOTERA ,  Koh ONO ,  Takahiro HORIE ,  Tomohiro YAMASAKI ,  Satoshi KOYAMA ,  Satoshi OBIKA ,  Yuya KASAHARA

IPC: C12N15/113 ,  A61P9/00

CPC classification number: C12N15/113 ,  A61P9/00 ,  C12N2310/11 ,  C12N2310/32 ,  C12N2310/3341 ,  C12N2310/315

Abstract: A prophylactic or therapeutic agent for an aneurysm comprising a miR-33b inhibiting substance, preferably an antisense oligonucleotide against miR-33b, as an active ingredient.

公开(公告)号：US20190008886A1

公开(公告)日：2019-01-10

申请号：US16068163

申请日：2017-01-05

Applicant: OSAKA UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Masayuki NAKAMORI ,  Hideki MOCHIZUKI ,  Satoshi OBIKA ,  Takanori YOKOTA ,  Tetuya NAGATA ,  Yuya KASAHARA

IPC: A61K31/712 ,  C12N15/113 ,  C07K14/47 ,  A61P25/28 ,  A61P25/16

Abstract: The present invention can provide a nucleic acid medicine which has a higher effect and a more prolonged effect of inhibiting the expression of α-synudein can be provided. Disclosed is the oligonucleotide or a pharmacologically acceptable salt thereof, the oligonucleotide containing at least one nucleoside structure represented by Formula (I): (where each of Base and A are defined substituent or structure), can bind to an α-synudein gene, has activity for inhibiting expression of the α-synudein gene, and is complementary to the α-synudein gene, and the oligonucleotide has a length of twelve to twenty bases.

公开(公告)号：US20210317459A1

公开(公告)日：2021-10-14

申请号：US17250806

申请日：2019-09-04

Applicant: OSAKA UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION ,  NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY

Inventor： Akira KIKUCHI ,  Shinji MATSUMOTO ,  Satoshi OBIKA ,  Yuya KASAHARA ,  Takumi FUKUMOTO

IPC: C12N15/113 ,  A61P35/04

Abstract: The purpose of the present invention is to provide an antisense oligonucleotide that targets an ARL4C molecule and exerts an antitumor effect in vivo, and a nucleic acid drug using the antisense oligonucleotide. An antisense oligonucleotide that has a base sequence consisting of at least 10 consecutive bases contained in the base sequence represented by SEQ ID NO: 1. This antisense oligonucleotide targets an ARL4C molecule and thus can inhibit the expression of ARL4C in a tumor cell in vitro and suppress the migration and proliferation thereof. When systemically administered, moreover, the antisense oligonucleotide can exert an excellent antitumor effect in vivo too.

公开(公告)号：US20200056178A1

公开(公告)日：2020-02-20

申请号：US16487762

申请日：2018-02-20

Applicant: Osaka University

Inventor： Satoshi OBIKA ,  Reiko WAKI ,  Takao INOUE ,  Tokuyuki YOSHIDA ,  Kunihiko MORIHIRO ,  Yuya KASAHARA ,  Atsushi MIKAMI

IPC: C12N15/113 ,  A61K31/7115 ,  A61K31/712

Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2′,4′-bridged nucleic acids, 2′,4′-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2′,4′-non-bridged nucleic acid residue(s) is/are modified.

公开(公告)号：US20220170020A1

公开(公告)日：2022-06-02

申请号：US17666341

申请日：2022-02-07

Applicant: Osaka University

Inventor： Satoshi OBIKA ,  Reiko WAKI ,  Takao INOUE ,  Tokuyuki YOSHIDA ,  Kunihiko MORIHIRO ,  Yuya KASAHARA ,  Atsushi MIKAMI

IPC: C12N15/113 ,  A61K31/7115 ,  A61K31/712

Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2′,4′-bridged nucleic acids, 2′,4′-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2′,4′-non-bridged nucleic acid residue(s) is/are modified.

公开(公告)号：US20210277398A1

公开(公告)日：2021-09-09

申请号：US17261653

申请日：2019-07-31

Applicant: Osaka University ,  National Institutes of Biomedical Innovation, Health and Nutrition ,  Luxna Biotech Co., Ltd.

Inventor： Masahito SHIMOJO ,  Satoshi OBIKA ,  Yuya KASAHARA ,  Takao SUZUKI ,  Masaki YAMAGAMI ,  Tadashi UMEMOTO

IPC: C12N15/113

Abstract: Disclosed is an oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide comprises at least one defined nucleoside structure, can bind to a human nSR100 gene and has human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer, and is complementary to a defined target region. Further, disclosed is an nSR100 gene expression inhibitor and a cancer therapeutic agent containing the oligonucleotide or the pharmacologically acceptable salt thereof. The cancer therapeutic agent is used for treatment of small cell lung cancer, prostate cancer, or breast cancer.